EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan

Hiroko Machida iD, Koji Matsuo iD, Takahiro Higashi iD, Daisuke Aoki iD, Takayuki Enomoto iD, Aikou Okamoto iD, Hidetaka Katabuchi iD, Satoru Nagase iD, Masaki Mandai iD, Nobuo Yaegashi iD, Wataru Yamagami iD, Mikio Mikami iD

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e61 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Hiroko Machida und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Cost-Benefit Analysis, Hospitals, High-Volume, Quality-Adjusted Life Years. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BMS, Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Hospital treatment volume affects survival in patients with endometrial cancer; notably, initial treatment at high-volume centers improves survival outcomes. Our study assessed the effect of hospital treatment volume on cost-effectiveness and survival outcomes in patients with endometrial cancer in Japan. METHODS: A decision-analytic model was evaluated using the following variables and their impact on cost-effectiveness: 1) hospital treatment volume (low-, intermediate-, and high-volume centers) and 2) postoperative recurrent risk factors based on pathological findings (high- and intermediate-risk or low-risk). Data were obtained from the Japan Society of Obstetrics and Gynecology database, systematic literature searches, and the Japanese Diagnosis Procedure Combination database. Quality-adjusted life years (QALY) was used as a measure of effectiveness. The model was built from a public healthcare perspective and the impact of uncertainty was assessed using sensitivity analyses. RESULTS: A base-case analysis showed that the incremental cost-effectiveness ratio at high-volume centers was below a willingness-to-pay (WTP) threshold of ¥5,000,000 with a maximum of ¥3,777,830/4.28 QALY for the high- and intermediate-risk group, and ¥2,316,695/4.57 QALY for the low-risk group. Treatment at the high-volume centers showed better efficiency and cost-effectiveness in both strategies compared to intermediate- or low-volume centers. Sensitivity analyses showed that the model outcome was robust to changes in input values. With the WTP threshold, treatment at high-volume centers remained cost-effective in at least 73.6% and 78.2% of iterations for high- and intermediate-risk, and low-risk groups, respectively. CONCLUSION: Treatment at high-volume centers is the most cost-effective strategy for guiding treatment centralization in patients with endometrial cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsCost-Benefit AnalysisHospitals, High-VolumeQuality-Adjusted Life YearsHumansFemaleJapanHospitals, Low-VolumeDecision Support TechniquesMiddle AgedAgedCost-Effectiveness Analysis

Stichwörter der Autor:innen

Cost-Effectiveness AnalysisEndometrial CancerHospitalQuality-Adjusted Life YearsSurvival

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan.
  • Department of Obstetrics and Gynecology, Toyohashi Municipal Hospital, Aichi, Japan.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
  • Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
  • National Cancer Center Japan, Institute for Cancer Control, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, International University of Health and Welfare Graduate School, Tokyo, Japan.

ORCID-Profile: Hiroko Machida, Koji Matsuo, Takahiro Higashi, Daisuke Aoki, Takayuki Enomoto, Aikou Okamoto, Hidetaka Katabuchi, Satoru Nagase, Masaki Mandai, Nobuo Yaegashi, Wataru Yamagami, Mikio Mikami

Förderung

  • BMS
  • Bristol-Myers Squibb

Zitieren

APA

Machida, H., Matsuo, K., Higashi, T., Aoki, D., Enomoto, T., Okamoto, A., Katabuchi, H., Nagase, S., Mandai, M., Yaegashi, N., Yamagami, W., & Mikami, M. (2024). Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e61

Vancouver

Machida H, Matsuo K, Higashi T, Aoki D, Enomoto T, Okamoto A, et al. Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e61

BibTeX
@article{Machida2024,
  author = {Machida, Hiroko and Matsuo, Koji and Higashi, Takahiro and Aoki, Daisuke and Enomoto, Takayuki and Okamoto, Aikou and Katabuchi, Hidetaka and Nagase, Satoru and Mandai, Masaki and Yaegashi, Nobuo and Yamagami, Wataru and Mikami, Mikio},
  title = {Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e61}
}
Kostenlos starten →